Published in Eur J Clin Pharmacol on December 29, 2007
Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatol Ther (Heidelb) (2014) 0.92
The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol (2014) 0.76
Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 3.53
Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) (2004) 2.37
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2001) 2.11
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol (1998) 1.88
Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol (2006) 1.57
Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol (2005) 1.47
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
Methylenetetrahydrofolate reductase 677C-->T variant modulates folate status response to controlled folate intakes in young women. J Nutr (2003) 1.12
Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol (2005) 1.11
Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) (2002) 1.07
HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem (2003) 0.98
Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther (2003) 0.92
Conventional systemic agents for psoriasis. A systematic review. J Rheumatol (2006) 0.90
Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis. Basic Clin Pharmacol Toxicol (2005) 0.88
The transport and accumulation of methotrexate in human erythrocytes. Cancer (1981) 0.86
Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol (2000) 0.86
Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis (1994) 0.85
Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol (2004) 0.84
Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol (1988) 0.84
Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol (1998) 0.84
Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol (2004) 0.82
Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol (2002) 0.81
Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet (2003) 0.80
Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol (2000) 0.79
Methotrexate for psoriasis: current European practice. A postal survey. J Eur Acad Dermatol Venereol (2005) 0.76
Epidemiology of Helicobacter pylori infection in the Czech Republic. Helicobacter (2006) 1.04
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther (2008) 0.86
The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: preliminary results. Neuro Endocrinol Lett (2006) 0.86
Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis. Acta Oncol (2009) 0.85
Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther (2012) 0.84
Brain levels of GABA, glutamate and aspartate in sociable, aggressive and timid mice: an in vivo microdialysis study. Neuro Endocrinol Lett (2009) 0.84
Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer. Tumour Biol (2011) 0.83
A new technique for measurement of water permeability of stomatous cuticular membranes isolated from Hedera helix leaves. J Exp Bot (2004) 0.83
Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Int Urol Nephrol (2014) 0.83
In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology (2007) 0.82
Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol (2002) 0.81
677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol (2010) 0.81
The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals (2008) 0.80
Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet (2003) 0.80
Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology (2009) 0.80
The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem Res Toxicol (2009) 0.80
Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol Pharm Bull (2009) 0.79
Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase. Int Orthop (2009) 0.79
Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 czech women. Clin Appl Thromb Hemost (2008) 0.78
Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. Biopharm Drug Dispos (2008) 0.78
Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum Exp Toxicol (2009) 0.78
[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma]. Cas Lek Cesk (2011) 0.78
Minipig as a model for drug metabolism in man: comparison of in vitro and in vivo metabolism of propafenone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2003) 0.77
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. Can J Physiol Pharmacol (2012) 0.77
Pharmacokinetic study of two acetylcholinesterase reactivators, trimedoxime and newly synthesized oxime K027, in rat plasma. J Appl Toxicol (2011) 0.77
Changes of serum calcium, magnesium and parathyroid hormone induced by hemodialysis with citrate-enriched dialysis solution. Kidney Blood Press Res (2015) 0.77
Comparative pharmacokinetics of N(ω)-hydroxy-nor-L-arginine, an arginase inhibitor, after single-dose intravenous, intraperitoneal and intratracheal administration to brown Norway rats. Xenobiotica (2013) 0.77
Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS. Int Angiol (2015) 0.77
The cytotoxic effect of α-tomatine in MCF-7 human adenocarcinoma breast cancer cells depends on its interaction with cholesterol in incubation media and does not involve apoptosis induction. Oncol Rep (2013) 0.76
Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2. Toxicology (2012) 0.76
Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock (2014) 0.76
Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology (2008) 0.76
Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats. Pharmacol Res (2009) 0.76
P-glycoprotein function and expression during obstructive cholestasis in rats. Eur J Gastroenterol Hepatol (2008) 0.76
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology (2013) 0.76
Brief daily episode of normoxia inhibits cardioprotection conferred by chronic continuous hypoxia. Role of oxidative stress and BKCa channels. Curr Pharm Des (2013) 0.75
Our experience with atopy patch tests with aeroallergens. Acta Medica (Hradec Kralove) (2013) 0.75
[The importance of DNA analysis of C282Y, H63D and S65C mutations in the HFE gene]. Cas Lek Cesk (2012) 0.75
Molecular heterosis in metamphetamine abusers. Int J Psychiatry Clin Pract (2007) 0.75
The effect of wheat allergy on the course of atopic eczema in patients over 14 years of age. Acta Medica (Hradec Kralove) (2011) 0.75
Troponins in experimental studies. Acta Medica (Hradec Kralove) (2002) 0.75
Inhibition of aspartate aminotransferase by glycation in vitro under various conditions. J Enzyme Inhib Med Chem (2002) 0.75
High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate. Arzneimittelforschung (2010) 0.75
Model systems based on experimental animals for studies on drug metabolism in man: (mini)pig cytochromes P450 3A29 and 2E1. Basic Clin Pharmacol Toxicol (2005) 0.75
New potential nonsteroidal anti-inflammatory drugs with antileukotrienic effects: influence on model proteins with catalytic activity. Acta Medica (Hradec Kralove) (2002) 0.75
Oral administration of quercetin is unable to protect against isoproterenol cardiotoxicity. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Evaluation of cow's milk allergy in a large group of adolescent and adult patients with atopic dermatitis. Acta Medica (Hradec Kralove) (2012) 0.75